Edgestream Partners, L.P. Alkermes Plc. Transaction History

Edgestream Partners, L.P.

$2.23 Billion
Q3 2024

A detailed history of Edgestream Partners, L.P. transactions in Alkermes Plc. stock. As of the latest transaction made, Edgestream Partners, L.P. holds 270,671 shares of ALKS stock, worth $7.63 Million. This represents 0.34% of its overall portfolio holdings.

Number of Shares

270,671

Previous 85,023 218.35%

Holding current value

$7.63 Million

Previous $2.05 Million 269.74%

% of portfolio

0.34%

Previous 0.1%

11 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2024 Nov 14, 2024	BUY	$23.01 - $28.55 $4.27 Million - $5.3 Million	185,648 Added 218.35%	270,671 $7.58 Million
Q2 2024 Aug 09, 2024	BUY	$23.21 - $27.24 $125,658 - $147,477	5,414 Added 6.8%	85,023 $2.05 Million
Q1 2024 May 10, 2024	BUY	$26.4 - $32.56 $1.42 Million - $1.75 Million	53,600 Added 206.08%	79,609 $2.16 Million
Q4 2023 Feb 14, 2024	SELL	$23.37 - $28.68 $181,140 - $222,298	-7,751 Reduced 22.96%	26,009 $721,000
Q3 2023 Nov 14, 2023	BUY	$27.17 - $31.97 $545,573 - $641,957	20,080 Added 146.78%	33,760 $945,000
Q2 2023 Aug 10, 2023	BUY	$28.34 - $33.63 $387,691 - $460,058	13,680 New	13,680 $428,000
Q4 2022 Feb 13, 2023	BUY	$21.94 - $26.24 $951,581 - $1.14 Million	43,372 Added 143.41%	73,615 $1.92 Million
Q3 2022 Nov 14, 2022	BUY	$22.0 - $31.87 $665,346 - $963,844	30,243 New	30,243 $675,000
Q2 2022 Aug 12, 2022	SELL	$26.4 - $30.54 $1.81 Million - $2.1 Million	-68,686 Closed	0 $0
Q1 2022 May 13, 2022	SELL	$23.07 - $27.99 $3.18 Million - $3.85 Million	-137,722 Reduced 66.72%	68,686 $1.81 Million
Q4 2021 Feb 15, 2022	BUY	$21.47 - $32.08 $4.43 Million - $6.62 Million	206,408 New	206,408 $4.8 Million

Others Institutions Holding ALKS

# of Institutions

360

Shares Held

181M

Call Options Held

175K

Put Options Held

96.6K

View Full List

About Alkermes plc.

Ticker ALKS
Exchange NASDAQ
Sector Healthcare
Industry Drug Manufacturers—Specialty & Generic
Shares Outstandng 164,254,000
Market Cap $4.63B
Description
Alkermes plc, a biopharmaceutical company, researches, develops, and commercializes pharmaceutical products to address unmet medical needs of patients in various therapeutic areas in the United States, Ireland, and internationally. Its marketed products include ARISTADA, an intramuscular injectable suspension for the treatment of schizophrenia; ...

More about ALKS

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Edgestream Partners, L.P., based on Form 13F filings with the SEC.

News

Stay updated on Edgestream Partners, L.P. with notifications on news.

Account

Edgestream Partners, L.P. Alkermes Plc. Transaction History